Publications
This study describes documented use and reported outcomes; it establishes neither efficacy nor safety and motivates rigorous prospective evaluation.
Leading the Conversation in Healthcare AI










































































Browse nference's publication below
BPC-157 Gray-market therapeutics Clinical-note surveillance
November 5, 2026
This study describes documented use and reported outcomes; it establishes neither efficacy nor safety and motivates rigorous prospective evaluation.

Neurosensory outcomes
GLP-1
November 4, 2026
In this observational study we found no evidence of a population-level excess of documented somatosensory or peripheral neuropathic phenotypes after semaglutide or tirzepatide initiation; the modestly lower incidence was within the range of systematic error indicated by the negative controls.

Zepbound
weight loss
October 21, 2026
While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

October 20, 2026
In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.
semaglutide
pregnancy
October 16, 2026
Overall, semaglutide prescribing during pregnancy was not associated with significant differences in maternal or newborn outcomes studied in this routine care setting.

Oral semaglutide
Orforglipron
September 28, 2026
In a small subset with 90-day follow-up weights, oral Wegovy was associated with greater early weight loss than Foundayo; comparative safety findings remain exploratory.

Oral semaglutide
Weight-loss response
September 20, 2026
Greater early weight loss tracked prior weight gain, faster dose escalation, and larger blood-pressure reductions.

Incretin therapies
Kidney biomarkers
September 3, 2026
The study explored organ-specific biomarker patterns across metabolic therapies.

of 13